SEQUOIA 5-YEAR FOLLOW-UP IN ARM C: FRONTLINE ZANUBRUTINIB MONOTHERAPY IN PATIENTS WITH DEL(17P) AND TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA R Dalfeor; CS Tam; P Ghia; M Shadman; T Munir; SS Opat; PA Walker; T Tian; J Hirata; JR Brown;

PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH 2 YEARS OF SURVIVAL FOLLOW-UP NN Shah; PL Zinzani; TA Eyre; K Izutsu; AJ Alencar; K Patel; T Munir; DE Tsai; ML Wang; LYGN Presenter;

GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY JR Brown; JA Woyach; K Patel; TA Eyre; Cy Cheah; P Ghia; W Jurczak; P Abada; WG Wierda; GFPN Presenter;